Ibrutinib Treatment of Pediatric Chronic Graft-versus-Host Disease: Primary Results from the Phase 1/2 iMAGINE Study
Paul A. Carpenter(Fred Hutch Cancer Center), Jean‐Hugues Dalle(Inserm), Seong Lin Khaw(Royal Children's Hospital), Andrew C. Harris(Primary Children's Hospital), Yihua Lee(AbbVie (United States)), Eneida R. Nemecek(Oregon Health & Science University), Benjamin Oshrine(Johns Hopkins All Children's Hospital), Justin T. Wahlstrom(University of California, San Francisco), Marco Zecca(Policlinico San Matteo Fondazione), Marta Verna(University of Milano-Bicocca), Kirk R. Schultz(University of British Columbia), Peter J. Shaw(Children's Hospital at Westmead), Keon Hee Yoo(Samsung Medical Center), Liudmila Zubarovskaya(Saint Petersburg State Pediatric Medical University), Sonali Chaudhury(Northwestern University), Giovanna Lucchini(Great Ormond Street Hospital), Hyoung Jin Kang(Seoul National University Hospital), Bin Cho(The Catholic University of Korea Seoul St. Mary's Hospital), Lori Styles(Vyne Therapeutics (United States)), Polina Stepensky(Hebrew University of Jerusalem)
Cited by 31
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
|Nature Medicine|2018|577